RecruitingPhase 1NCT06478693

A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC

A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including Hepatocellular Carcinoma

Sponsor

Myeloid Therapeutics

Enrollment

70 participants

Start Date

Jul 1, 2024

Study Type

INTERVENTIONAL

Conditions

Hepatocellular Carcinoma

Summary

This is a multicenter, open-label, Phase 1, first-in-human, dose-escalation study designed to assess the safety, tolerability and define the RP2D of MT-303 alone (Module 1) and in combination with Atezo/Bev (Module 2) in participants with advanced hepatocellular carcinoma expressing GPC3.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests MT-303, an experimental antibody therapy, in patients with advanced hepatocellular carcinoma (liver cancer) or other cancers that express a protein called GPC3, which is found on the surface of certain cancer cells. **You may be eligible if...** - You are 18 or older - You have confirmed advanced, recurrent, or metastatic liver cancer (HCC) or another GPC3-expressing cancer type - Your liver function is adequate (Child-Pugh Class A) - Your overall health is adequate (ECOG 0 or 1) **You may NOT be eligible if...** - You have active infection, including untreated hepatitis - Your cancer has spread to the brain or the membranes around it - You have had a liver transplant or are on the transplant waiting list - You have uncontrolled variceal bleeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMT-303

MT-303

DRUGMT-303 +Atezolizumab + Bevacizumab

MT-303 in combination with Atezo/Bev

Locations(9)

St Vincent's Hospital

Sydney, New South Wales, Australia

Integrated Clinical Oncology Network (ICON) Pty Ltd

Woolloongabba, Queensland, Australia

The Alfred Hospital

Melbourne, Victoria, Australia

Linear Clinical Research

Murdoch, Western Australia, Australia

Pusan National Univesity Hospital

Busan, South Korea

Cha University Bundang Medical Center

Gyeonggi-do, South Korea

Seoul National University Hospital

Seoul, South Korea

National Taiwan University Hospital

Taipei, Taiwan

Taipei Tzu Chi Hospital

Taipei, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06478693

Related Trials

A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis

NCT0609677961 locations

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

NCT065031461 location

Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma

NCT044727671 location

SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma

NCT072747741 location

Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma

NCT069022461 location